Investigating the role of SIRT5 in Acute Myeloid Leukemia
Official title: Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
Funded at Versiti Wisconsin, INC. · NIH-10886567 · Data updated 2026-11-12
This study is looking at how a specific protein called SIRT5 influences Acute Myeloid Leukemia (AML) to find new ways to treat this tough blood cancer and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $358,565 |
| NIH project number | 5R01CA254354-06 |
| Project ID | NIH-10886567 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia who may benefit from novel therapeutic approaches.
✕Less likely to help
Patients with other types of leukemia or those who do not have a diagnosis of Acute Myeloid Leukemia may not receive benefits from this research.
What this research studies
This research focuses on understanding how the metabolic regulator SIRT5 affects Acute Myeloid Leukemia (AML), a type of aggressive blood cancer. The study aims to identify new therapeutic targets by examining primary AML cells in conditions that mimic the bone marrow environment. By using advanced techniques like shRNA screening, researchers hope to uncover vulnerabilities in AML cells that could lead to more effective treatments. The goal is to find ways to overcome the limitations of current therapies and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that are more effective for patients with Acute Myeloid Leukemia.
How similar studies have gone: Other research has shown promise in targeting metabolic regulators in cancer, suggesting that this approach could be effective in AML as well.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Deininger, Michael W. — Versiti Wisconsin, INC.
- Study coordinator: Deininger, Michael W.
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.